Sino Biopharmaceutical Limited
SBMFFOTCHealthcare● Active
$0.63
+$0.00(+0.00%)
Market Cap$11.3B
P/E Ratio—
52W High$1.24
52W Low$0.37
Sino Biopharmaceutical Limited (SBMFF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
SBMFF · earnings · updated Jun 9, 2026
Latest Earnings
Q1 FY2026Report Date: Mar 26, 2026EPS Actual
$0.00
Est. $0.01 · -83.3%
Revenue
$2.04B
Est. $2.06B · -1.1%
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Mar 26, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
SBMFF reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 26, 2026 | $0.02 | — | — | — | $2.97B | — |
| ▼ Q1 FY2026 | Mar 26, 2026 | $0.01 | $0.00 | -83.3% | $2.04B | $2.06B | -1.1% |
| ◌ Q1 FY2026 | Mar 18, 2026 | $0.01 | — | — | — | $0.98B | — |
| ▼ Q3 FY2025 | Aug 18, 2025 | $0.02 | $0.01 | -21.7% | $1.23B | $2.44B | -49.8% |
| ▲ Q1 FY2025 | Mar 20, 2025 | $0.01 | $0.01 | +17.8% | $1.21B | $1.94B | -37.8% |
| — Q4 FY2024 | Dec 31, 2024 | — | $0.00 | — | $0.89B | — | — |
| — Q3 FY2024 | Sep 30, 2024 | — | $0.00 | — | $0.93B | — | — |
| ▲ Q3 FY2024 | Aug 13, 2024 | $0.01 | $0.01 | +17.1% | $1.09B | $2.08B | -47.6% |
Q3 FY2026
Aug 26, 2026
EPS Actual
—
EPS Est.
$0.02
EPS Surpr.
—
Revenue
—
Q1 FY2026
Mar 26, 2026Miss
EPS Actual
$0.00
EPS Est.
$0.01
EPS Surpr.
-83.3%
Revenue
$2.04B
Q1 FY2026
Mar 18, 2026
EPS Actual
—
EPS Est.
$0.01
EPS Surpr.
—
Revenue
—
Q3 FY2025
Aug 18, 2025Miss
EPS Actual
$0.01
EPS Est.
$0.02
EPS Surpr.
-21.7%
Revenue
$1.23B
Q1 FY2025
Mar 20, 2025Beat
EPS Actual
$0.01
EPS Est.
$0.01
EPS Surpr.
+17.8%
Revenue
$1.21B
Q4 FY2024
Dec 31, 2024
EPS Actual
$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
$0.89B
Q3 FY2024
Sep 30, 2024
EPS Actual
$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
$0.93B
Q3 FY2024
Aug 13, 2024Beat
EPS Actual
$0.01
EPS Est.
$0.01
EPS Surpr.
+17.1%
Revenue
$1.09B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2029 | $0.09 | $0.09 | $0.09 | 1 |
| Q4 FY2028 | $0.10 | $0.10 | $0.10 | 1 |
| Q3 FY2028 | $0.12 | $0.12 | $0.12 | 1 |
| Q2 FY2028 | $0.06 | $0.06 | $0.06 | 1 |
| Q1 FY2028 | $0.12 | $0.12 | $0.12 | 1 |
| Q4 FY2027 | $0.08 | $0.08 | $0.08 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2029 | $15.8B | $15.8B | $15.8B | 1 |
| Q4 FY2028 | $16.9B | $16.9B | $16.9B | 1 |
| Q3 FY2028 | $20.4B | $20.4B | $20.4B | 1 |
| Q2 FY2028 | $14.2B | $14.2B | $14.2B | 1 |
| Q1 FY2028 | $16.8B | $16.8B | $16.8B | 1 |
| Q4 FY2027 | $13.4B | $13.4B | $13.4B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q1 FY2026 | Mar 26, 2026 | -83.3% | $0.76 | $0.76 | +0.07% |
| ▼ Q3 FY2025 | Aug 18, 2025 | -21.7% | $0.99 | $0.99 | +0.00% |
| ▲ Q1 FY2025 | Mar 20, 2025 | +17.8% | $0.42 | $0.42 | +0.00% |
| — Q4 FY2024 | Dec 31, 2024 | — | $0.41 | $0.41 | +0.00% |
| — Q3 FY2024 | Sep 30, 2024 | — | $0.47 | $0.47 | +0.00% |
| ▲ Q3 FY2024 | Aug 13, 2024 | +17.1% | $0.34 | $0.34 | +0.12% |
| ▲ Q2 FY2024 | Apr 8, 2024 | +0.2% | $0.42 | $0.36 | -12.97% |
| ▼ Q2 FY2023 | Jun 30, 2023 | -51.5% | $0.39 | $0.39 | +0.00% |
Q1 FY2026+0.07%
Report Date
Mar 26, 2026
EPS Beat/Miss
-83.3%
Price Before
$0.76
Price After
$0.76
Q3 FY2025+0.00%
Report Date
Aug 18, 2025
EPS Beat/Miss
-21.7%
Price Before
$0.99
Price After
$0.99
Q1 FY2025+0.00%
Report Date
Mar 20, 2025
EPS Beat/Miss
+17.8%
Price Before
$0.42
Price After
$0.42
Q4 FY2024+0.00%
Report Date
Dec 31, 2024
EPS Beat/Miss
—
Price Before
$0.41
Price After
$0.41
Q3 FY2024+0.00%
Report Date
Sep 30, 2024
EPS Beat/Miss
—
Price Before
$0.47
Price After
$0.47
Q3 FY2024+0.12%
Report Date
Aug 13, 2024
EPS Beat/Miss
+17.1%
Price Before
$0.34
Price After
$0.34
Q2 FY2024-12.97%
Report Date
Apr 8, 2024
EPS Beat/Miss
+0.2%
Price Before
$0.42
Price After
$0.36
Q2 FY2023+0.00%
Report Date
Jun 30, 2023
EPS Beat/Miss
-51.5%
Price Before
$0.39
Price After
$0.39
Avg Beat Reaction-4.28%
Avg Miss Reaction+0.02%
Beat Rate3 / 8 quarters
Largest Move-12.97% (Q2 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: SBMFF ends December
Sino Biopharmaceutical Limited (SBMFF) most recently reported earnings on March 26, 2026 for Q1 FY2026, posting EPS of $0.00 — missing the analyst consensus of $0.01 by -83.3%. The next SBMFF earnings date is expected around September 1, 2026.
Each quarter, investors track SBMFF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. SBMFF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
SBMFF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
SBMFF earnings · 5 questionsSino Biopharmaceutical Limited's next earnings report is expected around September 1, 2026. SBMFF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; SBMFF historically reports after market close (AMC).
SBMFF earnings datewhen is SBMFF earningsSBMFF next earnings datewhen does SBMFF report earningsSBMFF earnings calendar
▸ Source: FMP · Sino Biopharmaceutical Limited SEC filings · US GAAP · Sino Biopharmaceutical Limited SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026